Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Aris

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Vaccine|September 9, 2017
Erratum to "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults" [Vaccine 34 (2016) 3156-3163]Geert Leroux-Roels, Pierre Van Damme, Wouter Haazen, et al.
The Pediatric Infectious Disease Journal|October 16, 2010
Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccineTerry Nolan, Peter Richmond, Helen Marshall, et al.
Open Forum Infectious Diseases|April 8, 2022
Increased Risk of Herpes Zoster in Adults ≥50 Years Old Diagnosed With COVID-19 in the United StatesAmit Bhavsar, Germain Lonnet, Chengbin Wang, et al.
Infectious Diseases and Therapy|June 25, 2021
Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance DatabaseCatherine Weil-Olivier, Muhamed-Kheir Taha, Corinne Emery, et al.
The Pediatric Infectious Disease Journal|January 15, 2010
Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of ageGary S Marshall, Colin D Marchant, Mark Blatter, et al.
COPD|April 19, 2021
Burden of Pertussis in COPD: A Retrospective Database Study in EnglandEmmanuel Aris, Lauriane Harrington, Amit Bhavsar, et al.
Human Vaccines & Immunotherapeutics|May 24, 2012
Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trialsKristina Bryant, Jodie McVernon, Colin Marchant, et al.
Human Vaccines & Immunotherapeutics|June 30, 2020
Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of AgeTimo Vesikari, Paula Peyrani, Chris Webber, et al.
Human Vaccines & Immunotherapeutics|February 14, 2012
The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY)Stephen Rinderknecht, Kristina Bryant, Terry Nolan, et al.
Journal of Asthma and Allergy|January 20, 2022
Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in EnglandAmit Bhavsar, Emmanuel Aris, Lauriane Harrington, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Vaccine|September 9, 2017
Erratum to "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults" [Vaccine 34 (2016) 3156-3163]Geert Leroux-Roels, Pierre Van Damme, Wouter Haazen, et al.
The Pediatric Infectious Disease Journal|October 16, 2010
Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccineTerry Nolan, Peter Richmond, Helen Marshall, et al.
Open Forum Infectious Diseases|April 8, 2022
Increased Risk of Herpes Zoster in Adults ≥50 Years Old Diagnosed With COVID-19 in the United StatesAmit Bhavsar, Germain Lonnet, Chengbin Wang, et al.
Infectious Diseases and Therapy|June 25, 2021
Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance DatabaseCatherine Weil-Olivier, Muhamed-Kheir Taha, Corinne Emery, et al.
The Pediatric Infectious Disease Journal|January 15, 2010
Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of ageGary S Marshall, Colin D Marchant, Mark Blatter, et al.
COPD|April 19, 2021
Burden of Pertussis in COPD: A Retrospective Database Study in EnglandEmmanuel Aris, Lauriane Harrington, Amit Bhavsar, et al.
Human Vaccines & Immunotherapeutics|May 24, 2012
Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trialsKristina Bryant, Jodie McVernon, Colin Marchant, et al.
Human Vaccines & Immunotherapeutics|June 30, 2020
Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of AgeTimo Vesikari, Paula Peyrani, Chris Webber, et al.
Human Vaccines & Immunotherapeutics|February 14, 2012
The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY)Stephen Rinderknecht, Kristina Bryant, Terry Nolan, et al.
Journal of Asthma and Allergy|January 20, 2022
Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in EnglandAmit Bhavsar, Emmanuel Aris, Lauriane Harrington, et al.
Pageof 4